Background: Since Food and Drug Administration approved the first Hybrid Closed Loop system in September 2016, more advanced devices have been commercialized. These systems combine insulin infusion with continuous Glucose Monitoring. A Minimed 780G is considered one of the most Advanced Hybrid Closed Loop systems at this time available in pediatric and adult subjects with type 1 diabetes. Previous studies showed an obvious improvement in glycemic parameters in comparison with those traditional ways as multiple dose injection in adults only, not including children. Objectives: to compare Glycemic Control among children and adolescents with type 1 Diabetes Mellitus through two methods of treatment: Minimed 780G versus Multiple Daily Injections. Patients and methods: This prospective cohort study was conducted on 48 children and adolescents diagnosed with type I Diabetes Mellitus and on Hybrid closed loop system of Minimed 780G or MDI, who were followed in Endocrinology Outpatient clinic at Military Hospitals. The patients were divided into two groups: 32 patients on Multiple Daily Injections and 16 patients on Hybrid Closed Loop System Insulin Pump Minimed 780. Results: A significant difference was found between the two groups regarding Pediatric intensive care unit (PICU) admission (p<0.001) as it was significantly higher in MDI group than G780 group over a period of six months (from March to August) during 2023. HbA1c readings were significantly higher in MDI group compared to G780 group during the period of study. Cholesterol & triglycerides were significantly higher in MDI group compared to G780 group (p=0.015) during 6-month study while no significant differences were found between the two groups regarding very low density, low-density and high-density lipoprotein levels.